Work

Molecular and immune correlates of response to first-line de-escalated chemotherapy plus penpulimab and anlotinib in advanced cervical cancer

Year: 2025

Type: article

Abstract: We describe the results of a multicenter, single-arm phase 2 study of first-line de-escalated platinum-based chemotherapy with concurrent and maintenance therapy with penpulimab (an anti-PD-1 antibody) combined with anlotinib (an antiangiogenic multikinase inhibitor) in 34 patients with PD-L1 positive, persistent, recurrent or metastatic cervical cancer.

Source: Zenodo (CERN European Organization for Nuclear Research)

DOI: 10.5281/zenodo.15694365

Author: Shengtao, Zhou

Institution: West China Second University Hospital of Sichuan University

Language: English

Topic: Endometrial and Cervical Cancer Treatments

Subfield: Obstetrics and Gynecology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: green

OpenAlex ID: W6967941613

FWCI:

Cites:

Cited by:

Related to: